請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67863完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林?輝(Feng-huei Lin) | |
| dc.contributor.author | Chia-Yu Hung | en |
| dc.contributor.author | 洪嘉鈺 | zh_TW |
| dc.date.accessioned | 2021-06-17T01:54:33Z | - |
| dc.date.available | 2019-07-27 | |
| dc.date.copyright | 2017-07-27 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-07-24 | |
| dc.identifier.citation | 1. Shyong, Y.J., et al., Mesoporous Hydroxyapatite as Olanzapine Carrier Provides a Long-Acting Effect in Antidepression Treatment. J Med Chem, 2015. 58(21): p. 8463-74.
2. Yu, J., The etiology and exercise implications of sarcopenia in the elderly. International Journal of Nursing Sciences, 2015. 2(2): p. 199-203. 3. Lang, T., et al., Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int, 2010. 21(4): p. 543-59. 4. Bowen, T.S., G. Schuler, and V. Adams, Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle, 2015. 6(3): p. 197-207. 5. Chen, L.K., et al., Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc, 2014. 15(2): p. 95-101. 6. Argiles, J.M., et al., Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol, 2015. 22: p. 100-6. 7. Cruz-Jentoft, A.J., et al., Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing, 2014. 43(6): p. 748-59. 8. Gonzalez, M.C. and S.B. Heymsfield, Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: what are we really estimating? J Cachexia Sarcopenia Muscle, 2017. 8(2): p. 187-189. 9. Pansarasa, O., et al., Oral amino acid supplementation counteracts age-induced sarcopenia in elderly rats. Am J Cardiol, 2008. 101(11A): p. 35E-41E. 10. Khor, S.C., et al., Vitamin E in sarcopenia: current evidences on its role in prevention and treatment. Oxid Med Cell Longev, 2014. 2014: p. 914853. 11. Wang, C., et al., A polysaccharide isolated from the medicinal herb Bletilla striata induces endothelial cells proliferation and vascular endothelial growth factor expression in vitro. Biotechnol Lett, 2006. 28(8): p. 539-43. 12. Liechty, W.B., et al., Polymers for drug delivery systems. Annu Rev Chem Biomol Eng, 2010. 1: p. 149-73. 13. Bruno, B.J., G.D. Miller, and C.S. Lim, Basics and recent advances in peptide and protein drug delivery. Ther Deliv, 2013. 4(11): p. 1443-67. 14. Prausnitz, M.R. and R. Langer, Transdermal drug delivery. Nat Biotechnol, 2008. 26(11): p. 1261-8. 15. Jin, J.F., et al., The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence, 2015. 9: p. 923-42. 16. Fu, Y. and W.J. Kao, Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv, 2010. 7(4): p. 429-44. 17. Zucker, D., et al., Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J Control Release, 2009. 139(1): p. 73-80. 18. Nokhodchi, A., et al., The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts, 2012. 2(4): p. 175-87. 19. Vijayalakshmi, P., et al., Development of extended zero-order release gliclazide tablets by central composite design. Drug Dev Ind Pharm, 2008. 34(1): p. 33-45. 20. Kadam, P.D. and H.H. Chuan, Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. Int Urogynecol J, 2016. 27(3): p. 505. 21. Jiang, F., et al., Antioxidant, antityrosinase and antitumor activity comparison: the potential utilization of fibrous root part of Bletilla striata (Thunb.) Reichb.f. PLoS One, 2013. 8(2): p. e58004. 22. Jitaru, S., et al., The use of bioceramics in endodontics - literature review. Clujul Med, 2016. 89(4): p. 470-473. 23. Szymczyna, B.R., et al., Synergy of NMR, computation, and X-ray crystallography for structural biology. Structure, 2009. 17(4): p. 499-507. 24. Palmer, L.C., et al., Biomimetic systems for hydroxyapatite mineralization inspired by bone and enamel. Chem Rev, 2008. 108(11): p. 4754-83. 25. D'Elia, N.L., et al., Bone-repair properties of biodegradable hydroxyapatite nano-rod superstructures. Nanoscale, 2015. 7(44): p. 18751-62. 26. Oledzka, E., et al., Selenium-Substituted Hydroxyapatite/Biodegradable Polymer/Pamidronate Combined Scaffold for the Therapy of Bone Tumour. Int J Mol Sci, 2015. 16(9): p. 22205-22. 27. Wang, Y., et al., A new glucomannan from Bletilla striata: structural and anti-fibrosis effects. Fitoterapia, 2014. 92: p. 72-8. 28. Mollah, M.Y., M. Kesmez, and D.L. Cocke, An X-ray diffraction (XRD) and Fourier transform infrared spectroscopic (FT-IR) investigation of the long-term effect on the solidification/stabilization (S/S) of arsenic(V) in Portland cement type-V. Sci Total Environ, 2004. 325(1-3): p. 255-62. 29. Kacher, J., et al., Bragg's Law diffraction simulations for electron backscatter diffraction analysis. Ultramicroscopy, 2009. 109(9): p. 1148-56. 30. Winey, M., et al., Conventional transmission electron microscopy. Mol Biol Cell, 2014. 25(3): p. 319-23. 31. van Apeldoorn, A.A., et al., Parallel high-resolution confocal Raman SEM analysis of inorganic and organic bone matrix constituents. J R Soc Interface, 2005. 2(2): p. 39-45. 32. Baker, M.J., et al., Using Fourier transform IR spectroscopy to analyze biological materials. Nat Protoc, 2014. 9(8): p. 1771-91. 33. Song, Y., A. Tahmasebi, and J. Yu, Co-pyrolysis of pine sawdust and lignite in a thermogravimetric analyzer and a fixed-bed reactor. Bioresour Technol, 2014. 174: p. 204-11. 34. Vashist, S.K. and C.K. Dixit, Interference of N-hydroxysuccinimide with bicinchoninic acid protein assay. Biochem Biophys Res Commun, 2011. 411(2): p. 455-7. 35. Yin, L.M., et al., Long term and standard incubations of WST-1 reagent reflect the same inhibitory trend of cell viability in rat airway smooth muscle cells. Int J Med Sci, 2013. 10(1): p. 68-72. 36. Chan, F.K., K. Moriwaki, and M.J. De Rosa, Detection of necrosis by release of lactate dehydrogenase activity. Methods Mol Biol, 2013. 979: p. 65-70. 37. Kong, L., et al., Physicochemical characterization of the polysaccharide from Bletilla striata: effect of drying method. Carbohydr Polym, 2015. 125: p. 1-8. 38. Peter, J.C., et al., Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats. J Cachexia Sarcopenia Muscle, 2013. 4(1): p. 79-88. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67863 | - |
| dc.description.abstract | 肌少症是一個隨著年齡老化而造成的肌肉質量減少以及肌肉功能衰退之疾病。有鑑於目前的醫療技術在肌少症發病之後並沒有相當有效及無副作用的治療方式，且氫氧基磷灰石為身體中骨骼及牙齒的組成分之一，有著良好的生物相容性及生物可降解性，不僅能夠補充老年人身體中所缺失的鈣質更能透過藥物長期釋放的方式減少所需施打藥物的次數及頻率，降低年長者所受之痛。本實驗以預防勝於治療的初衷作為出發點，先對實驗的大鼠施打以氫氧基磷灰石(Hydroxyapatie , HAp)乘載白芨多醣體(Bletilla striata , BSP)之藥物，再施打從大腸桿菌中所萃取出的脂多醣，誘導類似肌少症所產生的肌肉損傷及發炎反應。觀察實驗組及對照組 (單純施打脂多醣誘導肌肉損傷及發炎反應) 之間的差別，並以肌肉拉力測試、小動物跑步機之肌耐力檢測、血液分析、組織切片及MRI等檢測結果來分析本實驗之藥物是否有達到預防肌肉損傷及抗發炎的效果。
根據ISO-10993之標準本實驗所合成之HAp、BSP及HAp-BSP是無生物毒性且有良好生物相容性。經由TGA熱重分析檢測，本實驗所合成之HAp-BSP載藥量約為13%，且BSP揮發溫度落在300 oC與參考文獻中所提及白芨多醣體揮發溫度相同。本實驗成功利用LPS誘導類似肌少症之肌肉損傷及發炎反應，且利用HAp-BSP能成功預防LPS所引發的症狀，證實HAp-BSP有其抗氧化及促進組織增生的效果。 | zh_TW |
| dc.description.abstract | Sarcopenia is a disease of muscle mass loss and muscle function decline caused by aging. Because there are no effective and no side effects treatments to treat sarcopenia, and hydroxyapatite is one of the components of bones and teeth in human body, has well biocompatibility and biodegradability. Not only can supplement the body of the lack of calcium in the body but also through the drug long-term Release to reduce the drug injection frequency, mitigate the pain suffered by the elderly. In this study, the starting point is that prevention is better than treatment . Inject HAp─BSP first then inject lipopoly- saccharide extracted from E.coli which is going to induce muscle injury and re- duction muscle mass that are similar to the symptoms of sarcopenia. To observe the difference between the experimental group and the control group (induced by LPS-induced muscle injury and inflammatory reaction), and to analyze the results of muscle tension test, muscle endurance test, blood analysis, HE stain and MRI image to find whether HAp─BSP can prevent muscle injury and anti-inflammatory. According to ISO-10993, HAp, BSP and HAp-BSP prepared in this experiment are biologically toxic and have good biocompatibility. Through the TGA analysis, HAp-BSP drug loading efficiency is about 13%, and the BSP volatilization at 300 oC, which is the same as the re- ference. In this study, we successfully used LPS to induce muscle injury that similar to sarcopenia, and HAp-BSP could prevent the symptoms caused by LPS. It was confirmed that HAp-BSP had its anti-oxidation and promoting tissue capacity. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T01:54:33Z (GMT). No. of bitstreams: 1 ntu-106-R04548053-1.pdf: 2604469 bytes, checksum: cde91e621003116eb7eb1170c541cf6f (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 目錄
中文摘要 1 英文摘要 2 第一章 緒論 3 1-1-1 肌少症的介紹 3 1-1-2 肌少症的診斷 5 1-1-4 肌少症的治療方式 6 1-2-1 常見投藥方式 8 1-3-1 傳統中藥白芨之簡介 11 1-3-2 12 第二章 基礎理論 13 2-1-1 生醫陶瓷 13 2-1-2 晶體學介紹 14 2-1-3 生物礦化 15 2-1-4 仿生陶瓷 15 2-2-1 氫氧基磷灰石 16 2-2-2 傳統中藥白芨 17 2-3-1 化學共沉法 18 2-3-2 X光繞射分析(XRD) 18 2-3-3 穿透式電子顯微鏡觀察 (TEM) 21 2-3-4 場發射掃描式電子顯微鏡 (SEM) 22 2-3-5 紅外線光譜儀分析(FTIR) 22 2-4-1 熱重分析儀 (TGA) 23 2-4-2 蛋白質濃度測定(BCA protein assay kit) 24 2-5-1 紫外光/可見光光譜儀 (UV-Vis) 25 2-6-1細胞存活檢測─WST-1試驗 25 2-6-2 細胞毒性檢測─LDH試驗 26 第三章 實驗方法 27 表3- 1實驗儀器及製造廠商 27 表3- 2使用的化學藥品及製造商 28 3-3-1 實驗架構 29 3-3-2 材料製備 30 3-4-1 場發射掃描式電子顯微鏡操作 32 3-4-2 穿透式電子顯微鏡操作 33 3-4-3 紅外線光譜儀操作 33 3-5-1 熱重分析儀操作 33 3-6-1 紫外光/可見光光譜儀操作 34 3-7-1 3T3細胞株培養 35 3-7-3 LDH試驗 36 3-8-1 實驗動物製備 37 3-8-2 動物實驗分組 37 3-8-3 大鼠體重檢測 37 第四章 實驗結果 38 4-3-1 熱重分析測試結果 42 4-5-1 WST-1 試驗結果 43 4-5-2 LDH試驗結果 44 4-6-1 體重變化分析 45 4-6-2 血液分析 46 4-6-3 握力檢測 47 4-6-4 跑步機測試 48 4-6-5 組織切片 49 4-6-6 核磁共振攝影 (MRI) 50 第五章 討論 51 第六章 結論 53 參考文獻 54 | |
| dc.language.iso | zh-TW | |
| dc.title | 以氫氧基磷灰石作為載體乘載白芨多醣體作為肌少症的預防用藥 | zh_TW |
| dc.title | Using HAp as Bletilla striata polysaccharide carrier to
prevent muscle injured by sarcopenia | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 姚俊旭,陳克紹,吳信志,郭士民 | |
| dc.subject.keyword | 白芨,肌少症,氫氧基磷灰石, | zh_TW |
| dc.subject.keyword | bletilla striata,sarcopenia,hydroxyapatite, | en |
| dc.relation.page | 56 | |
| dc.identifier.doi | 10.6342/NTU201701777 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-07-24 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| 顯示於系所單位： | 醫學工程學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 目前未授權公開取用 | 2.54 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。